Chrystal Jensen - Cerus Chief Counsel
| CERS Stock | USD 1.82 0.06 3.41% |
Executive
Chrystal Jensen is Chief Counsel of Cerus
| Age | 53 |
| Address | 1220 Concord Avenue, Concord, CA, United States, 94520 |
| Phone | 925 288 6000 |
| Web | https://www.cerus.com |
Chrystal Jensen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Chrystal Jensen against Cerus stock is an integral part of due diligence when investing in Cerus. Chrystal Jensen insider activity provides valuable insight into whether Cerus is net buyers or sellers over its current business cycle. Note, Cerus insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cerus'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Chrystal Jensen over three months ago Disposition of 16667 shares by Chrystal Jensen of Cerus at 2.065 subject to Rule 16b-3 |
Cerus Management Efficiency
The company has return on total asset (ROA) of (0.0373) % which means that it has lost $0.0373 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3831) %, meaning that it created substantial loss on money invested by shareholders. Cerus' management efficiency ratios could be used to measure how well Cerus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.2 in 2024. Return On Capital Employed is likely to drop to -0.24 in 2024. At this time, Cerus' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 34.3 M in 2024, whereas Total Current Assets are likely to drop slightly above 99.5 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Ross Mansbach | Establishment Labs Holdings | 57 | |
| Michael CFA | Rapid Micro Biosystems | N/A | |
| Dr JD | Cutera Inc | 53 | |
| Helen Leupold | Bioventus | N/A | |
| Rachel Osbeck | Treace Medical Concepts | N/A | |
| CPA CFA | MaxCyte | 55 | |
| Tracy Founds | Glaukos Corp | N/A | |
| Melanie Gebauer | Accuray Incorporated | N/A | |
| Harold Tamayo | Axogen Inc | N/A | |
| MBA BS | Bioventus | N/A | |
| Joel Batts | Orthopediatrics Corp | N/A | |
| David Crawford | Bioventus | N/A | |
| Todd Brown | Accuray Incorporated | N/A | |
| Julie Dewey | Orthofix Medical | 63 | |
| Steve Kreider | Cutera Inc | N/A | |
| Sean Wirtjes | Rapid Micro Biosystems | 55 | |
| Terry Lubben | Treace Medical Concepts | 59 | |
| David Lehman | Pulmonx Corp | 63 | |
| Roberto Donadello | Orthofix Medical | N/A | |
| Jeremy JD | Sight Sciences | 54 | |
| Stuart Drummond | Cutera Inc | 58 | |
Management Performance
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.0373 |
Cerus Leadership Team
Elected by the shareholders, the Cerus' board of directors comprises two types of representatives: Cerus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cerus. The board's role is to monitor Cerus' management team and ensure that shareholders' interests are well served. Cerus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cerus' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthew Notarianni, Director Relations | ||
| Richard Benjamin, Chief Medical Officer | ||
| Kevin Green, CFO and VP of Fin. | ||
| William Greenman, CEO and President and Director | ||
| Carol Moore, Sr. VP of Regulatory Affairs, Quality and Clinical | ||
| Lainie Corten, Sr. Director, Global Marketing & Investor Relations | ||
| Vivek Jayaraman, Chief Commercial Officer | ||
| Chrystal Jensen, Chief Counsel | ||
| Laurence MD, CoFounder Officer | ||
| Jessica Hanover, Vice Affairs | ||
| Chrystal Menard, Chief Legal Officer | ||
| Lori Roll, VP Secretary | ||
| Kevin CPA, VP CFO | ||
| Dr MBChB, Chief Officer | ||
| Laurence Corash, Senior Vice President Chief Medical and Chief Scientific Officer, Director | ||
| Alicia Goodman, Chief Officer | ||
| Chrystal JD, Chief Counsel | ||
| Nina Mufti, Senior Development |
Cerus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cerus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.0373 | ||||
| Profit Margin | (0.11) % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 360.34 M | ||||
| Shares Outstanding | 185.72 M | ||||
| Shares Owned By Insiders | 3.27 % | ||||
| Shares Owned By Institutions | 79.26 % | ||||
| Number Of Shares Shorted | 6.92 M | ||||
| Price To Earning | (4.70) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cerus Stock Analysis
When running Cerus' price analysis, check to measure Cerus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cerus is operating at the current time. Most of Cerus' value examination focuses on studying past and present price action to predict the probability of Cerus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cerus' price. Additionally, you may evaluate how the addition of Cerus to your portfolios can decrease your overall portfolio volatility.